Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PP-001 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Inflammation
NCT03769454Phase 1Completed
- Sponsor
- Panoptes Pharma
- Start
- Nov 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PaniDrop in Keratoconjunctivitis (KC) and ocular surface disease (OSD) (8 cohorts), sponsored by Panoptes Pharma. Primary endpoint: Evaluation of safety and tolerability by determining treatment emergent adverse events at 20 days. Started Nov 2018; status: completed.
02
Drugs
PaniDrop
03
Conditions
Keratoconjunctivitis (KC)ocular surface disease (OSD)
Beyond the preview
Go deeper on NCT03769454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769454.